| Douglas Scott Mccracken, MD | |
|
605 S George St, Suite 200, York, PA 17401-3160 | |
| (717) 851-2334 | |
| (717) 851-3498 |
| Full Name | Douglas Scott Mccracken |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 15 Years |
| Location | 605 S George St, York, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407080963 | NPI | - | NPPES |
| 418500 | Other | PA | UPMC |
| 30123296 | Other | PA | AMERIHEALTH MERCY-WGER |
| 30152969 | Other | PA | AMERIHEALTH CARITAS PA - WMG - CAREEXPRESS |
| 30153213 | Other | PA | AMERIHEALTH CARITAS PA - WMG - WS READYCARE |
| P009970 | Other | PA | GATEWAY |
| 102729724 | Medicaid | PA | |
| 30120315 | Other | PA | AMERIHEALTH MERCY - WMG |
| 2714642 | Other | PA | HIGHMARK BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD446011 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| York Hospital | York, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| York Hospital | 2961307467 | 84 |
News Archive
Today, Doctor Evidence, a clinical health research data provider, announced a content partnership with IBM Watson to contribute valuable clinical cancer research content to Watson's oncology solutions and developer ecosystem.
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.
The U.S. Preventive Services Task Force is scheduled to issue this recommendation on Tuesday, but advance press reports indicate the expert panel will urge the federal government to change its current position to recommend that men under age 75 forgo this widely used test.
Endogenous cannabinoids (endocannabinoids) play an important role in the brain and immune system. Bern researchers from the National Centre of Competence in Research "TransCure" have now found a new way to influence the endocannabinoid system.
Smoking is a known risk factor for the development of various forms of cancer. However, when it comes to the link between smoking and prostate cancer, the findings of previous studies have been contradictory. Now, for the first time, an international study led by MedUni Vienna and Basle University Hospital, has provided evidence of a clear link.
› Verified 3 days ago
| Entity Name | York Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326060492 PECOS PAC ID: 2961307467 Enrollment ID: O20031205000629 |
News Archive
Today, Doctor Evidence, a clinical health research data provider, announced a content partnership with IBM Watson to contribute valuable clinical cancer research content to Watson's oncology solutions and developer ecosystem.
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.
The U.S. Preventive Services Task Force is scheduled to issue this recommendation on Tuesday, but advance press reports indicate the expert panel will urge the federal government to change its current position to recommend that men under age 75 forgo this widely used test.
Endogenous cannabinoids (endocannabinoids) play an important role in the brain and immune system. Bern researchers from the National Centre of Competence in Research "TransCure" have now found a new way to influence the endocannabinoid system.
Smoking is a known risk factor for the development of various forms of cancer. However, when it comes to the link between smoking and prostate cancer, the findings of previous studies have been contradictory. Now, for the first time, an international study led by MedUni Vienna and Basle University Hospital, has provided evidence of a clear link.
› Verified 3 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
Today, Doctor Evidence, a clinical health research data provider, announced a content partnership with IBM Watson to contribute valuable clinical cancer research content to Watson's oncology solutions and developer ecosystem.
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.
The U.S. Preventive Services Task Force is scheduled to issue this recommendation on Tuesday, but advance press reports indicate the expert panel will urge the federal government to change its current position to recommend that men under age 75 forgo this widely used test.
Endogenous cannabinoids (endocannabinoids) play an important role in the brain and immune system. Bern researchers from the National Centre of Competence in Research "TransCure" have now found a new way to influence the endocannabinoid system.
Smoking is a known risk factor for the development of various forms of cancer. However, when it comes to the link between smoking and prostate cancer, the findings of previous studies have been contradictory. Now, for the first time, an international study led by MedUni Vienna and Basle University Hospital, has provided evidence of a clear link.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Douglas Scott Mccracken, MD 601 Memory Ln, York, PA 17402-2231 Ph: (717) 851-2334 | Douglas Scott Mccracken, MD 605 S George St, Suite 200, York, PA 17401-3160 Ph: (717) 851-2334 |
News Archive
Today, Doctor Evidence, a clinical health research data provider, announced a content partnership with IBM Watson to contribute valuable clinical cancer research content to Watson's oncology solutions and developer ecosystem.
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.
The U.S. Preventive Services Task Force is scheduled to issue this recommendation on Tuesday, but advance press reports indicate the expert panel will urge the federal government to change its current position to recommend that men under age 75 forgo this widely used test.
Endogenous cannabinoids (endocannabinoids) play an important role in the brain and immune system. Bern researchers from the National Centre of Competence in Research "TransCure" have now found a new way to influence the endocannabinoid system.
Smoking is a known risk factor for the development of various forms of cancer. However, when it comes to the link between smoking and prostate cancer, the findings of previous studies have been contradictory. Now, for the first time, an international study led by MedUni Vienna and Basle University Hospital, has provided evidence of a clear link.
› Verified 3 days ago
Dr. Sahil Jain, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1001 S George St, York Hospital, York, PA 17403 Phone: 717-851-2521 | |
Dr. Robert John Pizziketti, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 810 Bonneview Rd, York, PA 17402 Phone: 717-852-7766 Fax: 717-852-7862 | |
Dr. Michael A Wilson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4222 Lincoln Hwy, York, PA 17406 Phone: 717-812-2050 Fax: 717-812-2052 | |
Barry A Rott, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 S George St, York Hospital, York, PA 17403 Phone: 717-851-2521 Fax: 717-851-3535 | |
Asceline So Go, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 116 S George St, Suite 200, York, PA 17401 Phone: 717-845-8617 Fax: 717-854-6645 | |
Dr. Cathy P. Carpenter, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 80 Wyntre Brooke Dr, York, PA 17403 Phone: 717-741-9462 Fax: 717-741-4399 | |
Patrick Michael Sterling, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2251 Eastern Blvd, York, PA 17402 Phone: 717-840-2730 |